CA-FORESCOUT
24.1.2024 07:02:27 CET | Business Wire | Press release
In the last year, the world’s critical infrastructure – the medical, power, communications, waste, manufacturing, and transportation equipment that connects people and machines – has been under near-constant attack. Forescout Research – Vedere Labs recorded more than 420 million attacks between January and December 2023. That is 13 attacks per second, a 30% increase from 2022.
This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20240123671589/en/
2023 Global Threat Roundup Highlights from Forescout Research (Graphic: Business Wire)
Forescout, a global cybersecurity leader, unveiled the global findings of recorded attacks in its Adversary Engagement Environment (AEE) in the new report, “2023 Global Threat Roundup.” The AEE is maintained by Vedere Labs, a leading global team dedicated to uncovering vulnerabilities in and threats to critical infrastructure.
Despite the formidable challenges posed by the ongoing surge in cyber-activity, there is an optimistic path forward. Elisa Costante, VP of Research at Forescout Research – Vedere Labs, highlights the potential for positive change, stating, "While it's true that current efforts have fallen short in fully harnessing crucial technology to fortify critical assets and assess risks, there is an opportunity for improvement."
Read the blog: 2023 Global Threat Roundup: Trends in Cyberattacks, Exploits and Malware
Here are the top five insights from Forescout Research:
-
Not Yet Dormant: Log4j Dampens Software Library Exploits
Exploits against software libraries are witnessing a decline due to the waning popularity of Log4j exploits. This lull has given rise to a surge in exploits targeting network infrastructure and Internet of Things (IoT) devices.
Among the IoT landscape, the spotlight falls on IP cameras, building automation systems, and network-attached storage, emerging as the most sought-after targets for malicious actors.
Only 35% of exploited vulnerabilities made an appearance in the Cybersecurity and Infrastructure Security Agency's (CISA) Known Exploited Vulnerabilities (KEV) list. This divergence emphasizes the need for a proactive and comprehensive approach to cybersecurity, transcending reliance on known vulnerability databases.
-
OT Protocols Bear the Brunt
Operational Technology (OT) finds itself under relentless assault, with five key protocols bearing the brunt of persistent attacks. The primary targets include protocols used in industrial automation and power sectors, such as Modbus, subject to a staggering one-third of all attacks, closely followed by Ethernet/IP, Step7, and DNP3, each accounting for approximately 18% of the onslaught. IEC10X rounds out this list with 10% of attacks, leaving the remaining 2% distributed among various protocols, with BACnet emerging as the majority.
Building automation protocols, such as BACnet, experience less frequent scans. However, the relative scarcity of scans belies an alarming trend—targeted exploits against vulnerabilities in building automation devices are more prevalent.
-
Post-Exploitation Tactics Shift
Persistence tactics mark a 50% surge from 3% in 2022, along with discovery (roughly 25%) and execution (the other roughly 25%). While most observed commands used by threat actors remain targeted at generic Linux systems, a notable trend involves specific commands executed for network operating systems found on widely used routers.
-
Malware Families Remain Strong
Malware families persist as formidable threats. The Agent Tesla Remote Access Trojan (RAT) commands a significant 16% share of observed malicious activity. Following closely are variants of the Mirai botnet, comprising 15%, and the Redline info stealer, holding its ground at 10%.
Among command-and-control servers, Cobalt Strike emerges as the undisputed leader, commanding a substantial 46% share, trailed by Metasploit at 16%, and the emerging Sliver C2 at 13%. Most of these servers are in the United States, constituting 40% of the global landscape, with China and Russia following at 10% and 8%, respectively.
-
Threats Unleashed Across 163 Countries
Threat actors have cast a digital net far and wide, impacting 163 countries. The United States stands as the primary target, bearing the brunt with 168 malicious actors setting their sights on the nation. Other countries include the United Kingdom (88), Germany (77), India (72), and Japan (66).
The usual suspects boast high concentrations of threat actors: China (155), Russia (88), and Iran (45), collectively representing nearly half of all identified threat groups. The crosshairs of these malicious entities are predominantly fixed on three key sectors: Government, Financial Services, and Media and Entertainment. As the primary pillars of societal infrastructure, these industries are at the forefront of cyber warfare, emphasizing the need for heightened security measures and collaborative efforts.
Costante continues, “The key lies in achieving comprehensive visibility, ensuring real-time contextual awareness of every device, whether managed or unmanaged. By doing so, large enterprises can transition from a reactive defense posture to a more proactive approach, steering clear of the futile game of security whack-a-mole. This shift towards enhanced visibility and proactive defense strategies signals a brighter outlook for critical infrastructure.”
For more information, download the full report, “2023 Global Threat Roundup,” now at https://www.forescout.com/resources/research-report_2023-threat-roundup.
How Forescout Research Works
Forescout Research employs its Adversary Engagement Environment (AEE) to conduct analysis, leveraging a blend of real and simulated connected devices. This dynamic environment functions as a robust tool, enabling the pinpointing of incidents and the identification of intricate threat actor patterns at a granular level. The overarching objective is to elevate responses to complex critical infrastructure attacks by leveraging the detailed insights and understanding derived from this specialized deception environment. The AEE is maintained by Vedere Labs, a leading global team dedicated to uncovering vulnerabilities in and threats to critical infrastructure. Forescout products directly leverage this research, which is also shared openly with vendors, agencies, and other researchers.
About Forescout
Forescout Technologies, Inc., a global cybersecurity leader, continuously identifies, protects and helps ensure the compliance of all managed and unmanaged connected cyber assets – IT, IoT, IoMT and OT. For more than 20 years, Fortune 100 organizations and government agencies have trusted Forescout to provide vendor-agnostic, automated cybersecurity at scale. The Forescout® Platform delivers comprehensive capabilities for network security, risk and exposure management, and extended detection and response. With seamless context sharing and workflow orchestration via ecosystem partners, it enables customers to more effectively manage cyber risk and mitigate threats.
To view this piece of content from cts.businesswire.com, please give your consent at the top of this page.
View source version on businesswire.com: https://www.businesswire.com/news/home/20240123671589/en/
About Business Wire
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
Biocytogen Grants Taisho Pharmaceutical a License to its RenNano® Fully Human Heavy Chain-Only Antibody Discovery Platform30.3.2026 13:00:00 CEST | Press release
Biocytogen Pharmaceuticals (Beijing) Co., Ltd. (Biocytogen, SSE: 688796; HKEX: 02315), a global biotechnology company that drives the research and development of novel antibody-based drugs with innovative technologies, today announced that it has entered into a platform license agreement with Taisho Pharmaceutical Co., Ltd. (“Taisho”), granting Taisho the right to access and use Biocytogen’s proprietary RenNano® fully human heavy chain-only antibody (HCAbs) discovery platform for its internal research and development programs. Under the terms of the agreement, Taisho will leverage RenNano® mice to enable the generation and screening of fully human HCAbs in vivo and to support downstream research associated with antibody discovery. Financial terms of the agreement have not been disclosed. “We are very pleased to enter into this collaboration with Taisho,” said Dr. Yuelei Shen, President and CEO of Biocytogen. “RenNano® is a robust and powerful fully human VHH discovery platform that pro
Meiji Seika Pharma Invests in Centivax to Develop Next Generation Universal Vaccine Platform30.3.2026 13:00:00 CEST | Press release
Meiji Seika Pharma Co., Ltd. (Head Office: Chuo-ku, Tokyo, President and Representative Director: Toshiaki Nagasato) today announced a strategic investment in Centivax, Inc. (Head Office: South San Francisco, CA, USA), a biotechnology company developing next-generation vaccines and therapies for universal protection against highly diverse targets. Centivax’s lead program includes a universal seasonal influenza vaccine (Centi-Flu 01) currently in a Phase 1 clinical study. Unlike conventional seasonal flu vaccines, which must be manufactured annually based on recommended candidate vaccine viruses, Centivax’s platform focuses both antibody and cellular immune responses on conserved regions of the influenza virus that cannot mutate and are shared across strains and distant subtypes. This approach aims to generate broad, consistent, and durable immunity against both seasonal and pandemic influenza. Meiji’s strategic investment aims to accelerate the advancement of Centi-Flu 01 and further a
Samsung Biologics Strike: Labor Union Warns of CDMO Supply Chain Risks Following Overwhelming Vote30.3.2026 11:52:00 CEST | Press release
Union members overwhelmingly approve strike action with 95.52% voting in favor on a 95.38% turnout, clearing the final legal hurdle after mediation ceased.Union emphasizes this is a fight against structural corporate governance issues, citing unresolved allegations concerning unfair labor practices and ESG compliance risks.Management adhered to a group-level wage guideline rather than bargaining on the basis of Samsung Biologics' own performance, exposing a lack of independent bargaining authority. The Samsung Biologics Labor Union (President: Jaesung Park), representing approximately 75% of the company's total employees, announced today that its members have overwhelmingly voted in favor of a strike, with 95.52% voting in favor on a 95.38% turnout during a voting period from March 24 to March 29. Following the Incheon Regional Labor Relations Commission's decision to cease mediation, the union has now secured the legal mandate to strike. The union stressed that this strike is not mere
The Premier Jumping League (PJL) Launches with a Record-Breaking $300 Million Guaranteed Prize Pot, Defining a New Era for Showjumping30.3.2026 11:00:00 CEST | Press release
The PJL empowers riders to compete as full-time professional athletes while working towards a sustainable economic model for the sport. Backed by McCourt Global and shaped by a leadership team with decades of experience in equestrian competition, sport, and entertainment, the PJL sets a new, sustainable, and globally relevant standard for elite jumping. Sixteen teams will compete across fourteen iconic international venues throughout Europe, North America, and the Middle East when the inaugural season opens in March 2027. The Premier Jumping League (PJL) launches with a record-breaking $300 million guaranteed prize pot, defining a new era for showjumping. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260330990938/en/ Photography credits: Daniel Benson for The Premier Jumping League/ Wieden+Kennedy London Backed by McCourt Global and its Executive Chairman, Frank McCourt, the PJL is a groundbreaking global competition that e
Dompé Announces First Patient Enrolled in New Study of Intranasal NGF in Cerebral Palsy30.3.2026 11:00:00 CEST | Press release
Cerebral Palsy (CP) refers to a group of permanent disorders in the development of movement and posture, which causes activity limitations, and is attributed to non-progressive disturbances that occurred in the developing fetal or infant brain.1 Nerve growth factor (NGF) is a naturally-occurring protein that supports damaged nerve cells and improves nervous system signaling, Dompé is investigating whether intranasal NGF has the potential to improve movement and neurodevelopment and address underlying brain damage in people with CP. Dompé’s intranasal NGF platform builds on the Nobel Prize-winning discovery of neurobiologist Professor Rita Levi-Montalcini and biochemist Dr. Stanley Cohen. Dompé, a leading biopharmaceutical company with operations in Italy and in the U.S., announced that the first patient has been enrolled at the Agostino Gemelli IRCCS University Hospital in Rome, Italy, in a Phase 2 investigational study of an intranasal form of Nerve Growth Factor (NGF) (Cenegermin-bkb
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom
